u/rohan_cardoso

Disagree — that figure is from the diabetes programme and you are quoting it as an obesity endpoint.

Posted my first lane report here without the month and got asked for it. Fair, and the table is better for the fussiness.

nothing here is available as a prescription product, so read every thread with that in mind

monthly weigh-ins are enough at this stage

Not convinced by four data points. That is not a lane yet, it is an anecdote with a route attached.

Maintenance is the phase with the least published guidance and the most individual variation, which is precisely why board consensus here is worth less than usual.

Open-label extensions lose their randomisation. Anybody still enrolled at week 104 is a selected group and the numbers describe that group.

A confidence interval is the range of effects compatible with the data. Two trials with overlapping intervals have not disagreed, whatever their point estimates look like next to each other.

Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use, and that is a statement of fact rather than a disclaimer.

Discontinuation rates are a tolerability result. A trial with a strong efficacy number and heavy discontinuation is telling you two things and people only quote one.

SELECT was cardiovascular outcomes, not weight

phase 2 data only, and people quote it like it is a label

Argued for a week about a result and then read the limitations section, which conceded most of my opponent’s point.

How many shipments does your figure cover?

Agreed — and the decomposition matters. Most people are blaming the international leg for a last-mile problem.

Posted my first lane report here without the month and got asked for it. Fair, and the table is better for the fussiness.

seven days to ten to twelve is the sequence people here describe

Did you decide what maintenance would look like before you got here?

The habits from the losing phase are what carry it now. That is not inspirational, it is just what happened.

Cosigning on planning it in advance. Deciding what maintenance looks like while still losing is much easier than deciding it in a panic.

That is body weight change, not fat mass. The trials report the first and people quote it as the second.

How fast was the escalation? That is usually the variable that explains the reports.

Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.

the last mile is where most of the variance lives

boring is the objective now

Yes — the interval is the finding. A point estimate with a wide interval is a hypothesis in a nice font.

Body weight varies by a couple of kilos over days in stable people through fluid, glycogen and gut content. A range is not a trend.

Appetite returning before the scale moves follows from the mechanism: the appetite effect is the proximal one and weight is the lagging integrated out

Disagreeing with this bit: a two-kilo range is not drift and treating it as a problem creates one.

Push back: that is not a plateau, that is maintenance. You have arrived and you are describing it as a failure.

a quoted lead time you can hold them to is worth more than a fast one you cannot

This. Intention-to-treat versus completer analysis routinely moves the headline by several points.

A confidence interval is the range of effects compatible with the data. Two trials with overlapping intervals have not disagreed, whatever their point estimates look like next to each other.

The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.